



ISAF 2018

8 - 10 November 2018
Madrid, Spain



4th International Severe Asthma Forum



POCKET PROGRAMME

www.eaaci.org/isaf2018



Zuzana Diamant



Santiago Quirce



Matteo Bonini

WELCOME

Dear Colleagues and Friends,

On behalf of EAACI, we are delighted to welcome you to Madrid for the 4th International Severe Asthma Forum (ISAF).

Building upon the growing success of the previous ISAF meetings (Gothenburg 2012, Athens 2014, Manchester 2016), the aim of ISAF 2018 is to bring together scientists and clinicians, with a broad range of experience from junior scientists/doctors to key opinion leaders, at a focused meeting dedicated to all aspects of severe asthma.

In recent years, considerable progress has been made in understanding and treating severe asthma, including advances in phenotypic patterns and biomarkers and the availability of novel targeted treatments. These advances have unveiled the heterogeneous basis of asthma, whose nature and definition are being revisited in the light of the new pathophysiological and molecular findings that are continuously emerging.

ISAF is an interactive EAACI Focused Meeting and the programme is designed to facilitate discussions. We hope that this will encourage scientific collaborations and facilitate the translation of emerging discoveries into clinical practice to benefit our patients. We welcome speakers and participants from all over the world to share their knowledge and expertise with us and partake in a truly iterative interdisciplinary dialogue.

Madrid is a modern and vibrant city full of surprises. It has preserved the look and feel of many of its historic neighbourhoods and streets. Madrid is unique with its own rules and culture.

We want to encourage all of you to join the chariot of scientific advances, translational research and personalised medical care. We are confident that ISAF 2018 will be another milestone in this scientific journey.

Zuzana Diamant
ISAF 2018
Organising Chair & Asthma
Section Chair

Santiago Quirce
ISAF 2018
Local Secretary

Matteo Bonini
Asthma Section Secretary

COMMITTEES

ORGANISING COMMITTEE

Zuzana Diamant, The Netherlands
ISAF 2018 Organising Chair & Asthma
Section Chair

Santiago Quirce, Spain
ISAF 2018 Local Secretary

Matteo Bonini, United Kingdom
Asthma Section Secretary

SCIENTIFIC COMMITTEE

Sven Seys, Belgium
Marcin Kurowski, Poland
Enrico Heffler, Italy
Ömer Kalayci, Turkey
Susanne Vijverberg, The Netherlands
Martina Vasakova, Czech Republic
Mariana Couto, Portugal
Leif Bjermer, Sweden
Philippe Gevaert, Belgium
Jürgen Schwarze, United Kingdom
Apostolos Bossios, Sweden

LOCAL SCIENTIFIC AND ORGANISING COMMITTEE

Montserrat Alvaro Lozano, Spain
Oscar Palomares Gracia, Spain
Joaquín Sastre, Spain
Tomás Chivato, Spain
Dario Antolin-Amerigo, Spain
Silvia Sanchez-Garcia, Spain

EAACI PRESIDENT

Ioana Agache, Romania

EAACI VICE-PRESIDENT CONGRESSES

Carsten Schmidt-Weber, Germany

POTENTIAL CONFLICTS OF INTEREST DECLARATION

Please refer to the relevant event page
under the "Meetings" tab on www.eaaci.org
for a full conflict of interest declaration,
provided by the organising committee and
faculty members.


IMPORTANT ADDRESSES

VENUE

Meliá Avenida América
C/ Juan Ignacio Luca de Tena, 36
28027 Madrid, Spain
Tel.: +34 91 423 24 11
E-mail: almudena.velazquez@melia.com

ORGANISERS

EAACI Headquarters
Hagenholzstrasse 111
3rd Floor
8050 Zurich
Switzerland
Tel.: +41 44 205 55 33
E-mail: events@eaaci.org
Website: www.eaaci.org



All information at your fingertips
during the congress

- Search – View – Evaluate
- Regular updates to the scientific programme
- Use EAACI Free Internet WiFi to download
- Access to all abstracts



EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY

RHINA 2019
21 – 23 March 2019
Eastbourne, United Kingdom

 **RHINA**
European Rhinallergy Meeting

European Rhinallergy Meeting



www.eaaci.org/rhina2019

SCIENTIFIC PROGRAMME

THURSDAY, 8 NOVEMBER 2018

<p>12:00 - 13:45 <i>Foyer La Cheminee</i></p>	<p>REGISTRATION</p>
<p>13:45 - 14:00 <i>Zaragoza III & IV</i></p>	<p>WELCOME ADDRESS Ioana Agache, Romania Zuzana Diamant, The Netherlands Santiago Quirce, Spain</p>
<p>14:00 - 15:30 <i>Zaragoza III & IV</i></p>	<p>SEVERE ASTHMA: THE IMMUNOLOGICAL BASIS OF A HETEROGENEOUS SYNDROME CHAIRS: Ioana Agache, Romania Oscar Palomares, Spain</p> <p>14:00 - 14:45 Innate & Adaptive Pathways in Severe Asthma: Interactions & Pathogenesis Cezmi Akdis, Switzerland</p> <p>14:45 - 15:30 Different Endotypes and Phenotypes drive the Heterogeneity in Severe Asthma Liam Heaney, United Kingdom</p>
<p>15:30 - 16:00 <i>Toledo Rooms</i></p>	<p>COFFEE BREAK</p>
<p>16:00 - 18:00 <i>Zaragoza III & IV</i></p>	<p>DIAGNOSTIC CONTROVERSIES & COMORBIDITIES IN SEVERE ASTHMA (Parallel Session) CHAIRS: Joaquin Sastre, Spain Leif Bjermer, Sweden</p> <p>16:00 - 16:30 Establishing the Diagnosis: when is it (Severe) Asthma? Ioana Agache, Romania</p> <p>16:30 - 17:00 Comorbidities in Severe Asthma from ENT perspective Philippe Gevaert, Belgium</p> <p>17:00 - 17:30 Bronchiectasis in Severe Asthma: a new kid on the block Eva Polverino, Spain</p> <p>17:30 - 18:00 Psychological and Social Aspects in Severe Asthma Stefano Del Giacco, Italy</p>

THURSDAY, 8 NOVEMBER 2018

16:00 - 18:00 <i>Zaragoza I & II</i>	NOVEL DIAGNOSTIC & MONITORING TOOLS FOR SEVERE ASTHMA (Parallel Session) CHAIRS: Omer Kalayci, Turkey Ignacio Davila, Spain
16:00 - 16:30	Unravelling the Complexity of Tissue Inflammation in Uncontrolled and Severe Asthma Jonas Sten Erjefalt, Sweden
16:30 - 17:00	microRNAs: Emerging Markers of Asthma and Asthma Severity Victoria del Pozo, Spain
17:00 - 17:30	Breathonomics: what can Breath tell us about Uncontrolled Asthma? Paul Brinkman, The Netherlands
17:30 - 18:00	The Effect of Genes and Gene Expression Profiles on Asthma and treatment Outcomes Maarten van den Berge, The Netherlands
18:15 - 19:15	SATELLITE SYMPOSIUM 1 <i>(Further information on the page 19)</i>
19:15 - 20:00	E-POSTER DISCUSSION SESSION I EPO1-EP20
<i>Toledo Rooms</i>	Station 1 EPO1 - EPO5 CHAIRS: Montserrat Alvaro Lozano, Spain Stefano R Del Giacco, Italy EPO1 - Proinflammatory Cytokines (TNF And IL-6) And The Differential Expression Of MiRNAs In Severe Asthma Phenotype <i>Emilia Andrade Belitardo, Brasil</i> EPO2 - A Case Of Cross-Reactivity Between Omalizumab And Mepolizumab <i>Luís Amaral, Portugal</i> EPO3 - M2-Like Alveolar Macrophages Express Higher Levels Of PD-L1, PD-L2 And IP-10 In Allergic Asthmatic Patients <i>Lynn Greissel, Germany</i> EPO4 - Human Single-Cell BCR Analysis Of Putative IgE+ Memory B Cells Reveals Their Rare Existence <i>Rodrigo Jiménez-Saiz, Canada</i> EPO5 - Clinical Case: Reinke'S Edema Mimics Asthma Exacerbation <i>Nadezhda Knauer, Russia</i>

THURSDAY, 8 NOVEMBER 2018

<p>19:15 - 20:00</p> <p><i>Toledo Rooms</i></p>	<p>Station 2</p> <p>EP06 - EP10</p> <p>CHAIR: Sven Seys, Belgium</p> <p>EP06 - Case Of Asthma Associated With Heart Valves Disease Manifested After Neuraxial Anesthesia <i>Madona Devidze, Georgia</i></p> <p>EP07 - Features of Different Asthma Form in Children <i>Kateryna Khromykh, Ukraine</i></p> <p>EP08 - Clinical Symptoms Of Asthma In Children Depending Of The Phenotypical Variant <i>Kateryna Khromykh, Ukraine</i></p> <p>EP09 - 25-HYDROXYCHOLECALCIFEROL Content in Children with different form of Asthma <i>Kateryna Khromykh, Ukraine</i></p> <p>EP10 - Clinical Features of Asthma in Children with different levels of disease control <i>Kateryna Khromykh, Ukraine</i></p>
<p><i>Toledo Rooms</i></p>	<p>Station 3</p> <p>EP11 - EP15</p> <p>CHAIR: Victoria del Pozo, Spain</p> <p>EP11 - The Impact Of Chronic Epstein-Barr Viral Infection On Regulatory Cells In Patients With Severe Bronchial Asthma And COPD <i>Anna Konishcheva, Russia</i></p> <p>EP12 - Clinical Value Of The Reference Equation And Cut-Off Method For Spirometry Interpretation In Asthmatic Children <i>Snezhina Lazova, Bulgaria</i></p> <p>EP13 - The Gene- Oh The Gene Does It Play Some Role In Asthma? <i>Snezhina Lazova, Bulgaria</i></p> <p>EP14 - Quantification Of Alpha One Antitrypsin In Asthmatic Patients In An Allergy Department During Three Years <i>Laura Ortega-Martín, Spain</i></p> <p>EP15 - Tight Junction, Mucin And Inflammasome-Related Molecules Are Differentially Expressed In Eosinophilic, Mixed And Neutrophilic Experimental Asthma In Mice <i>Urszula Radzikowska, Switzerland</i></p>

THURSDAY, 8 NOVEMBER 2018

19:15 - 20:00 Station 4 **EP16 - EP20**

Toledo Rooms

CHAIR: Irina Bobolea, Spain

EP16 - Efficacy And Safety Of Omalizumab In Moderate-Severe Asthma Pediatric Patients: A Case Report
Sofia Martina Ramis Fernández, Spain

EP17 - Stability Of Serum MicroRNAs As A Diagnostic Biomarker In Asthma
Manuel Rial, Spain

EP18 - Serum MicroRNAs As Biomarkers Differencing ASTHMA From COPD, ACO And Healthy Subjects
José Rodrigo-Muñoz, Spain

EP19 - Peach Tree Pollen Induces Respiratory Symptoms In Exposed Children And Adolescents
Maria Luisa Somoza, Spain

EP20 - Sensitization To A New Peach Tree Pollen Allergen In Children
Maria Luisa Somoza, Spain

20:45 - 23:00 **WELCOME RECEPTION**

Royal Academy of
Medicine

FRIDAY, 9 NOVEMBER 2018

08:00 - 09:00	BREAKFAST SEMINAR - MEET THE EXPERT 1
<i>Tenerife I</i>	CHAIR: Dario Antolin Amerigo, Spain Severe occupational asthma: Clinical phenotypes and outcomes Joaquin Sastre, Spain Santiago Quirce, Spain
08:00 - 09:00	BREAKFAST SEMINAR - MEET THE EXPERT 2
<i>Tenerife II</i>	CHAIR: Enrico Heffler, Italy Is there a place for HDM SLIT in Severe Asthma? Giorgio Walter Canonica, Italy Moises Antonio Calderón, United Kingdom
09:00 - 10:30	FROM GENE AND ENVIRONMENTAL FACTORS TO CLINICAL BIOMARKERS IN SEVERE ASTHMA
<i>Zaragoza III & IV</i>	CHAIRS: Santiago Quirce, Spain Zuzana Diamant, The Netherlands
09:00 - 09:45	Interaction between genetic and environmental factors in SA Ignacio Davila, Spain
09:45 - 10:30	Biomarkers (help to define different phenotypes) in Severe Asthma Leif Bjermer, Sweden
10:30 - 11:00	COFFEE BREAK
<i>Toledo Rooms</i>	
11:00 - 13:00	NEW INSIGHTS INTO MECHANISMS AND TREATMENT OPTIONS OF NON-TYPE 2 ASTHMA (Parallel Session)
<i>Zaragoza III & IV</i>	CHAIRS: Leif Bjermer, Sweden Zuzana Diamant, The Netherlands
11:00 - 11:30	Neutrophilic asthma Sven Seys, Belgium
11:30 - 12:00	Non-inflammatory or pauci-granulocytic asthma Stelios Loukides, Greece
12:00 - 12:30	Non T2-high treatment strategies: there's light at the end of the tunnel Matteo Bonini, Italy
12:30 - 13:00	Role of the Airway Smooth Muscle in Severe Asthma Pascal Chanez, France

FRIDAY, 9 NOVEMBER 2018

<p>11:00 - 13:00 <i>Zaragoza I & II</i></p>	<p>CHILDHOOD SEVERE ASTHMA: FROM EPIDEMIOLOGY TO MANAGEMENT (Parallel Session) CHAIRS: Montserrat Alvaro Lozano, Spain Silvia Sanchez-Garcia, Spain</p>
<p>11:00 - 11:30</p>	<p>Virus-induced immune pathways in Asthma Development Jürgen Schwarze, United Kingdom</p>
<p>11:30 - 12:00</p>	<p>Preventable factors in difficult Childhood Asthma Andrew Bush, United Kingdom</p>
<p>12:00 - 12:30</p>	<p>Clinical phenotypes in childhood asthma and their impact on management Omer Kalayci, Turkey</p>
<p>12:30 - 13:00</p>	<p>Biologicals in pediatric asthma Irina Bobolea, Spain</p>
<p>13:00 - 14:30 <i>Toledo Rooms</i></p>	<p>LUNCH AND E-POSTER DISCUSSION SESSION II EP21-EP49</p> <p>Station 1 EP21 - EP28 CHAIRS: Marcin Kurowski, Poland Jose Olaguibel, Spain</p> <p>EP21 - Implementation Of Mandatory Electronic Multidisciplinary Pathway Improved Quality And Safety Of Asthma Care In Children; 3 Years' Experience <i>Manal Eldegeir, Saudi Arabia</i></p> <p>EP22 - Severe Asthma In Northern Sweden: Prevalence, Costs And Clinical Characteristics <i>Helena Backman, Sweden</i></p> <p>EP23 - Does Small Airway Predict Bronchial Hyperresponsiveness? An Observational Retrospective Study To Evaluate Small Airways Dysfunction <i>Diana Betancor, Spain</i></p> <p>EP24 - Real-Life Experience With Mepolizumab In A Severe Asthma Unit <i>Irina Bobolea, Spain</i></p> <p>EP25 - Exacerbation Rate Reduction With Mepolizumab, Split By Maintenance OCS Use And Eosinophil Levels. A Post-Hoc Analysis Of DREAM And MENSA Studies <i>Irina Bobolea, Spain</i></p> <p>EP26 - New Approach For Personalized Management Of Asthma: Clustering Analysis In Severe Asthmatic Responders To Omalizumab <i>Sheila Cabrejos Perotti, Spain</i></p>

FRIDAY, 9 NOVEMBER 2018

<p>13:00 - 14:30</p> <p>Toledo Rooms</p>	<p>Station 1 EP27 - Severe Asthma Is Associated With Higher Sinus Occupancy And Higher Nasal Polyp Frequency <i>José Antonio Castillo, Spain</i></p> <p>EP28 - CRTH2 MRNA Levels In Peripheral Blood In Adult Patients With Asthma <i>Ignacio Dávila, Spain</i></p>
<p>13:00 - 14:30</p> <p>Toledo Rooms</p>	<p>Station 2 EP29 - EP35</p> <p>CHAIR: Apostolos Bossios, Sweden</p> <p>EP29 - Antimicrobial Peptide C-Terminal HCAP18 CATHLICIDIN LL-37 and its content in Children Asthma <i>Kateryna Khromykh, Ukraine</i></p> <p>EP30 - Identification Of Novel Metabolomic Biomarkers Associated With HDM-Allergic Asthma Severity <i>Maria Escribese, Spain</i></p> <p>EP31 - Case Series Evaluation Of Asthmatic Patients Treated With Mepolizumab <i>Laura Feijoo Paz, Spain</i></p> <p>EP32 - High Altitude Climate Treatment Results In Long-Term Improved Asthma Control In Patients With Uncontrolled Severe Asthma <i>Karin Fieten, Switzerland</i></p> <p>EP33 - Patients With Severe Eosinophilic Asthma Treated With Mepolizumab: Results From Our Clinical Practice <i>Irene Hernández Martín, Spain</i></p> <p>EP34 - Population Of Patients With Severe Allergic Asthma In Poland Based On Data From The Drug Programme <i>Aleksandra Kucharczyk, Poland</i></p> <p>EP35 - Misdiagnosed "Severe Asthma" - The Devil Is In The Details <i>Snezhina Lazova, Bulgaria</i></p>
<p>13:00 - 14:30</p> <p>Toledo Rooms</p>	<p>Station 3 EP36 - EP42</p> <p>CHAIR: Moisés Antonio Calderón, United Kingdom</p> <p>EP36 - Severe Asthma Phenotypes <i>Mariana Lobato, Portugal</i></p> <p>EP37 - Effectiveness Of Bronchial Thermoplasty (BT) In Patients With Uncontrolled Asthma <i>Hanne Madsen, Denmark</i></p>

FRIDAY, 9 NOVEMBER 2018

13:00 - 14:30

Toledo Rooms

Station 3 EP38 - Asthma Exacerbations In The Paediatric Emergency Department: Relationship With Environmental Factors
M. Andreína Marques-Mejías, Spain

EP39 - Staphylococcal Enterotoxin B And Asthma: Impact On Severity And Asthma Exacerbations

M. Andreína Marques-Mejías, Spain

EP40 - Case Series Of Patients Treated With Reslizumab In A Dedicated Severe Asthma Unit

Beatriz Moya Camacho, Spain

EP41 - Efficacy And Safety Of Reslizumab In Severe Asthma Patients With Inadequate Response To Omalizumab: A Multicentre, Open-Label, Pilot Study

Luis Pérez De Llano, Spain

EP42 - Exposure To House Dust Mite Augments Inflammasome Activation During Rhinovirus Infection In Asthmatic Bronchial Epithelium

Urszula Radzikowska, Switzerland

13:00 - 14:30

Toledo Rooms

Station 4 EP43 - EP49

CHAIR: Oscar Palomares, Spain

EP43 - Efficacy Of Omalizumab To Achieve Asthma And Nasal Polyps Control After Aspirin Desensitization Failure: A Case Report

Marta Sánchez-Jareño, Spain

EP44 - OCS Use In Portuguese Respiratory Patients - Data From The National Prescription Database

Ana Sá-Sousa, Portugal

EP45 - Phenotypes Of Severe Asthma In Clinical Practice

Tomas Slisz, Czech Republic

EP46 - Assessment Of Omalizumab Treatment By Blood Eosinophil Count In Paediatric Patients With Severe Allergic Asthma From The Retrospective, Real-Life STELLAIR Study

Céline Thonnellier, France

EP47 - Real World OCS Use In Asthma In The Netherlands

Luciën Van Der Vlugt, The Netherlands

EP49 - Severe Occupational Asthma: Insights From A Multicenter European Cohort

Olivier Vandenplas, Belgium

13:15 - 14:15

Zaragoza I & II

SATELLITE SYMPOSIUM 2

(Further information on the page 19)

FRIDAY, 9 NOVEMBER 2018

14:30 - 16:00	PRO/CON SESSION
<i>Zaragoza III & IV</i>	
14:30 - 15:15	DEBATE 1 Do we need more Biologicals? CHAIR: Joaquin Sastre, Spain Pro: Ioana Agache, Romania Con: Leif Bjermer, Sweden
15:15 - 16:00	DEBATE 2 eHealth is useful in treatment of SA CHAIR: Sven Seys, Belgium Pro: Dario Antolin, Spain Con: Silvia Sanchez-Garcia, Spain
16:00 - 16:30	COFFEE BREAK
<i>Toledo Rooms</i>	
16:30 - 16:50	EAACI AIT ASTHMA GUIDELINES LAUNCHING
<i>Zaragoza III & IV</i>	Marek Jutel, Poland
16:50 - 17:50	ORAL ABSTRACT PRESENTATION OPO1-OPO4
<i>Zaragoza III & IV</i>	
	001 - 004
	CHAIRS: Dario Antolin Amerigo, Spain Ignacio Davila, Spain
16:50 - 17:05	001 - A Spanish Study On Unmet Clinical Needs In Patients With Uncontrolled Severe Asthma Luis Alejandro Pérez De Llano, Spain
17:05 - 17:20	002 - Exosomes From Asthmatic Eosinophils Impact On Remodelling Of Lung Structure Beatriz Sastre, Spain
17:20 - 17:35	003 - Definition Of Discriminatory Biomarkers Of Nonallergic And Allergic Asthma And Their Severity And The Role Of Methylation In Their Regulation Selene Baos, Spain
17:35 - 17:50	004 - Human Volatilome Analysis To Identify Individuals With Asthma In Clinical Settings Mariana Valente Farraia, Portugal
18:00 - 19:00	SATELLITE SYMPOSIUM 3
<i>Zaragoza I & II</i>	<i>(Further information on the page 19)</i>

SATURDAY, 10 NOVEMBER 2018

08:00 - 09:00	BREAKFAST SEMINAR - MEET THE EXPERT 3
<i>Tenerife I</i>	CHAIR: Jürgen Schwarze, United Kingdom Algorithms matching the right Biological with the right Patient Oscar Palomares, Spain Parameswaran Nair, Canada
08:00 - 09:00	BREAKFAST SEMINAR - MEET THE EXPERT 4
<i>Tenerife II</i>	CHAIR: Maarten van den Berge, The Netherlands Potential Role of Inhaled Allergen Challenge in Personalized Asthma Management Zuzana Diamant, The Netherlands Leif Bjermer, Sweden
09:00 - 10:30	TARGETED TREATMENT OF SEVERE ASTHMA: PRECISION MEDICINE IN CLINICAL PRACTICE
<i>Zaragoza III & IV</i>	CHAIRS: Ioana Agache, Romania Zuzana Diamant, The Netherlands
09:00 - 09:45	Update on Treatable Traits in Severe Asthma Charlotte Suppli Ulrik, Denmark
09:45 - 10:30	Emerging targeted therapies for Severe Asthma Parameswaran Nair, Canada
10:30 - 11:00	COFFEE BREAK
<i>Toledo Rooms</i>	
11:00 - 13:00	WORKSHOP 1 (Parallel Session)
<i>Zaragoza III & IV</i>	Lifestyle and its Effect on Asthma Control and Severity CHAIRS: Matteo Bonini, Italy Maarten van den Berge, The Netherlands
11:00 - 11:30	Effect of Exercise on Asthma and Asthma Control Marcin Kurowski, Poland
11:30 - 12:00	Severe Asthma and Metabolic Syndrome Apostolos Bossios, Sweden
12:00 - 12:30	Chlorine by-products: a problem for swimming pool workers and competition swimmers Mariana Couto, Portugal
12:30 - 13:00	Rehabilitation and education in severe asthma; a forgotten option? Antonio Spanevello, Italy

SATURDAY, 10 NOVEMBER 2018

11:00 - 13:00	WORKSHOP 2 (Parallel Session)
<i>Zaragoza I & II</i>	Consequences of Corticosteroid Treatment in Severe Asthma
	CHAIRS: Santiago Quirce, Spain Tomas Chivato, Spain
11:00 - 11:30	Inhalation technique: effect of know-how on adherence and asthma control
	Paul Hagedoorn, The Netherlands
11:30 - 12:00	Overview of Corticosteroid-related side effects
	Omar Usmani, United Kingdom
12:00 - 12:30	Pharmacoeconomic analysis of ICS-shadow side effects and costs
	Enrico Heffler, Italy
12:30 - 13:00	Strategies to reduce corticosteroids impact on severe asthma
	Martina Vasakova, Czech Republic
13:00 - 13:15	CLOSING AND PRIZE GIVING CEREMONY
<i>Zaragoza III & IV</i>	Joaquin Sastre, Spain



SAM 2019

4 - 6 April 2019
Munich, Germany



Skin Allergy Meeting

Joint meeting



www.eaaci.org/sam2019

SPONSORS AND EXHIBITORS

This section contains information that is promotional in nature,
distinct from the scientific/educational content.



Relevant outcomes in allergic asthma

Friday the 9th of November 2018 at 18.00-19.00
The Zaragoza I & II, Meliá Avenida América

Chair: Eike Wüstenberg

Early identification of asthma deterioration for modifying or preventing severe exacerbations. A clinical trial perspective.

Göran Eriksson, Sweden

Can we influence the natural course of asthma in routine care?

Eike Wüstenberg, Germany



SATELLITE SYMPOSIA

THURSDAY, 8 NOVEMBER 2018

**18:15 - 19:15 SATELLITE SYMPOSIUM
SANOFI-GENZYME AND REGENERON**
**Type 2 Inflammation in Severe Asthma:
Clinical and Therapeutic Implications**

Zaragoza I & II

Supported by:

SANOFI GENZYME
REGENERON

CHAIR: Santiago Quirce, Spain

Welcome and Introductions
Santiago Quirce, Spain

Defining Severe Asthma
Zuzana Diamant, The Netherlands

Type 2 Asthma: What Is it and What Mediators Drive It?
Santiago Quirce, Spain

Interactive Session: Identifying Type 2 Asthma in Clinical Practice
G. Walter Canonica, Italy

Closing Remarks and Panel Q&A
Santiago Quirce, Spain

FRIDAY, 9 NOVEMBER 2018

13:15 - 14:15 SATELLITE SYMPOSIUM NOVARTIS
New approaches in severe allergic asthma

Zaragoza I & II

Supported by:

NOVARTIS

CHAIR: Ignacio Dávila, Spain

Defining the severe allergic asthma patient candidate to biologics
Santiago Quirce, Spain

Component resolved diagnosis in severe allergic asthma
Olga Luengo, Spain

18:00 - 19:00 SATELLITE SYMPOSIUM ALK
Relevant outcomes in allergic asthma

Zaragoza I & II

Supported by:

ALK

CHAIR: Eike Wüstenberg, Germany

Early identification of asthma deterioration for modifying or preventing severe exacerbations. A clinical trial perspective
Göran Eriksson, Sweden

Can we influence the natural course of asthma in routine care?
Eike Wüstenberg, Germany

ISAF 2018 SPONSORS

PLATINUM SPONSOR

Sanofi Genzyme and Regeneron

Web: www.understandingtype2asthma.com

Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients' needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

SILVER SPONSOR

GSK

Web: www.gsk.com

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK has led the way in developing innovative medicines to advance the management of asthma and COPD for nearly 50 years. Over the last five years we have launched six innovative medicines responding to continued unmet patient need, despite existing therapies. This is an industry leading portfolio in breadth, depth and innovation, developed to reach the right patients, with the right treatment.

SPONSOR - WELCOME RECEPTION

SEAC - Spanish Society of Allergy and Clinical Immunology

Web: www.seaic.org

Founded in 1948, the Spanish Society of Allergy and Clinical Immunology (SEAC) is one of the oldest allergy societies in the world, currently with 1,460 active members (633 of the members in EAACI). There are 19 committees and commissions in our society and most of the affiliates attend adults and children. Some of our resources are: Periodic publications of positions paper (the last one: Vidal C, Antolín D, Rea J, no M, Valero A, Sastre J), Safety and Quality Recommendations in Allergy Medicine (Spanish acronym, RESCAL) *J Invest Allergol Clin Immunol* 2018; 28 (Suppl. 1): 1-39, a textbook of Allergy, 2nd edition 2015 (1700 pages), and a journal: *J Invest Allergol Clin Immunol*, impact factor 3.45.

ISAF 2018 EXHIBITORS

Novartis

Thermo Fisher Scientific

EAACI FOUNDER SPONSORS

EAACI gratefully acknowledges the support of its Founder Sponsors

PLATINUM LEVEL

Aimmune Therapeutics

ALK

Mylan

Novartis

SILVER LEVEL

Leti

Uriach

GOLD LEVEL

Allergopharma

AstraZeneca

Allergy Therapeutics

HAL Allergy

Stallergenes Greer


Thermo Fisher Scientific


EAACI thanks its sponsors
for supporting its Green
Meetings initiative



EAACI
goes green

VENUE FLOOR PLAN





TRAVEL GRANT AWARDEES OF ISAF 2018

A limited number of travel grants are offered to EAACI Junior Members who are the presenting authors of an accepted abstract. Those who are awarded a travel grant will receive travel costs refunded up to EUR 250 and will be reimbursed after the meeting.

- | | |
|---|------------------------------------|
| 1 Rodrigo Jiménez-Saiz, Canada | 6 Kateryna Khromykh, Ukraine |
| 2 Luciën Van Der Vlugt, The Netherlands | 7 Snezhina Lazova, Bulgaria |
| 3 Mariana Valente Farraia, Portugal | 8 Urszula Radzikowska, Switzerland |
| 4 Lynn S. Greissel, Germany | 9 Ana Sá-Sousa, Portugal |
| 5 Tomas Slisz, Czech Republic | |

GENERAL INFORMATION

ACCREDITATION – CME CREDITS

The ISAF 2018, International Severe Asthma Forum, Madrid, Spain, 08/11/2018-10/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **14 European CME credits** (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

INTERNET

Free WIFI will be offered in all meeting rooms throughout the duration of the event.

Network: Melia_Hotel

Password: -

MEDIA AND PRESS

Registered journalists have access to all scientific sessions. Please contact EAACI HQ to arrange interviews with clinicians and researchers who are presenting their work at ISAF 2018.

Contact details

EAACI Communications Team

EAACI Headquarters

Hagenholzstrasse 111

3rd Floor

8050 Zurich

Switzerland

Email: communications@eaaci.org

MOBILE PHONE & PHOTOGRAPHY POLICY

Please respect the meeting policy and switch off your mobile phone in all session rooms. Please also note that photography and/or video recording in session rooms is strictly forbidden.

NAME BADGES

Registration badges will be used during the meeting. For identification purposes and admission to session halls, participants are requested to wear their badges at all times. If you lose your badge, a new one can be purchased at a cost of EUR 20 from the Registration Desk.

REGISTRATION DESK

(FOYER LA CHEMINÉE)

The Registration Desk is located at the Ground Floor in front of the Lobby of the Cheminée Restaurant.

The opening hours are:

Thursday, 8 November 12:00 – 18:00

Friday, 9 November 07:30 – 18:00

Saturday, 10 November 07:30 – 14:00

EXHIBITION

The exhibition of the meeting will be held in the Toledo Room II. The opening hours of the exhibition are as follows:

Thursday, 8 November 12:00 - 20:00

Friday, 9 November 10:00 - 18:00

Saturday, 10 November 10:00 - 13:30

LANGUAGE

The official language of the meeting is English.

FILM, PHOTO AND VIDEO RECORDINGS

EAACI wants to create a comprehensive overview of the meeting interactions and events that may be of promotional interest to the academy. Accordingly, please be advised that you may be filmed or photographed at any time (in the session halls, poster areas, etc.).

INSURANCE/DISCLAIMER

EAACI will not be held liable for personal injuries or for loss of or damage to property incurred by participants at the ISAF 2018. Participants are encouraged to purchase insurance to cover loss incurred in the event of cancellation, medical expenses or damage to or loss of personal effects when traveling outside of their own countries. EAACI cannot be held liable for any hindrance or disruption of the event, proceedings arising from natural, political, social or economic events or other unforeseen incidents beyond its control.

Registration of a participant implies acceptance of this condition. The materials presented at this continuing medical education activity are made available for educational purposes only.

ENVIRONMENTAL POLICY

EAACI is committed to the reducing of the environmental impact of its meetings.

Reduce – Reuse – Recycle



EAACI
goes green



EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY

PAAM 2019

17 - 19 October 2019
Florence, Italy



6th Pediatric Allergy and Asthma Meeting

The background of the lower half of the poster is a photograph of Florence, Italy, showing the Duomo di Firenze (Cathedral of Santa Maria del Fiore) with its large red-tiled dome, the Giotto Campanile tower, and the surrounding cityscape under a hazy sky.

www.eaaci.org/paam2019



EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY

**SUBMIT
YOUR APPLICATION**
FROM 1 OCTOBER
TO 31 DECEMBER 2018



EAACI RESEARCH AND CLINICAL FELLOWSHIPS 2019

EAACI Fellowships support EAACI Junior Members who wish to spend time in a research or clinical center in another country with up to 20,000 EUR, for a 3 – 12 months period.

For more information please visit www.eaaci.org



European Academy of Allergy
and Clinical Immunology
1 – 5 June 2019
Lisbon, Portugal



EAACI Congress 2019

Mapping the new world
of allergy



www.eaaci.org

#eaaci2019